162 Thoracic Oncology Tumor Board Conference (120321)

Dallas, TX US
December 3, 2021

The multidisciplinary approach, including the medical, surgical and radiation areas of cancer therapy, providing a forum for the comprehensive care of complex cases in the management of thoracic cancer patients.

Target Audience

Faculty, Fellows, Residents, particularly those involved in the treatment of thoracic cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

1.    Follow established guidelines for diagnosis of thoracic cancer patients
2.    Incorporate multidisciplinary aspects in the care of thoracic cancer patients
3.    Offer available clinical research protocols to thoracic cancer patients

 

Course summary
Available credit: 
  • 1.00 AMA
  • 1.00 Attendance
  • 1.00 Ethics
Course opens: 
12/03/2021
Course expires: 
12/03/2021
Event starts: 
12/03/2021 - 1:00pm CST
Event ends: 
12/03/2021 - 2:00pm CST
Cost:
$0.00
Part of: 
162 Thoracic Oncology Tumor Board Conference 2021
Add to calendar: 
UT Southwestern Medical Center
5323 Harry Hines Blvd.
ND3.218
Dallas, TX 75390
United States

Course Chair: Kemp Kirnstein, MD

Moderator: Hak Choy, MD

 

 

 

 

 

Course Director(s)

John Waters, M.D.

has no relevant financial relationships to disclose at this time.
Moderator(s)

Kemp Kernstine, MD PhD

has no relevant financial relationships to disclose at this time.
Speaker(s)

Kiran Batra

has no relevant financial relationships to disclose at this time.

Liisa Bergmann, M.D., M.B.A.

has no relevant financial relationships to disclose at this time.

Jonathan Dowell

has a financial relationship (Professional Services) with Beigene;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with astra zeneca;.

David Gerber, MD

has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Independent contractor) with G1 Therapeutics;.
has a financial relationship (Grant Or Contract) with BerGenBio;.
has a financial relationship (Independent contractor) with Catalyst Therapeutics;.
has a financial relationship (Independent contractor) with BeiGene;.
has a financial relationship (Grant Or Contract) with Karyopharm;.
has a financial relationship (Stock) with Gilead;.
has a financial relationship (Independent contractor) with Mirati;.
has a financial relationship (Grant Or Contract) with Sagimet;.
has a financial relationship (Independent contractor) with Janssen;.

Randall Hughes, M.D, Professor of Internal Medicine

has a financial relationship (Employment) with Abbvie;.
has a financial relationship (Stock) with Pfizer;.

Puneeth Iyengar, MD, PhD

has a financial relationship (Professional Services) with AZ;.

Asha Kandathil

has no relevant financial relationships to disclose at this time.

Fernando Kay, MD, PhD

has no relevant financial relationships to disclose at this time.

VISHAL KUKKAR, MD

has no relevant financial relationships to disclose at this time.

Scott Reznik, MD

has no relevant financial relationships to disclose at this time.

Jennifer Schopp, MD

has no relevant financial relationships to disclose at this time.

Jose Torrealba, MD, Associate Professor

has no relevant financial relationships to disclose at this time.

John Waters, M.D.

has no relevant financial relationships to disclose at this time.

Kenneth Westover, MD, PhD, Associate Professor of Radiation Oncology and Biochemistry

has a financial relationship (Professional Services) with Vibliome Therapeutics;.
has a financial relationship (Independent contractor) with Amgen;.

Available Credit

  • 1.00 AMA
  • 1.00 Attendance
  • 1.00 Ethics

Price

Cost:
$0.00
Please login or create an account to take this course.